Astrazeneca (AZN) EPS (Diluted) Growth (3y) (2012 - 2026)
Astrazeneca (AZN) EPS (Diluted) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.00% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -59.00% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 11.31% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.35% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -130.36% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -28.10% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -34.20% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -35.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.66% |
| Mar 31, 2026 | -10.99% |
| Dec 31, 2025 | -6.86% |
| Sep 30, 2025 | 16.25% |
| Jun 30, 2025 | 104.80% |
| Mar 31, 2025 | 108.43% |
| Dec 31, 2024 | 56.50% |
| Sep 30, 2024 | 46.30% |
| Jun 30, 2024 | 11.07% |
| Mar 31, 2024 | 20.86% |
| Dec 31, 2023 | 0.20% |
| Sep 30, 2023 | 2.09% |
| Jun 30, 2023 | 21.46% |
| Mar 31, 2023 | 46.22% |
| Dec 31, 2022 | 31.44% |
| Sep 30, 2022 | 82.60% |
| Jun 30, 2022 | 8.99% |
| Mar 31, 2022 | -15.36% |
| Sep 30, 2021 | -98.14% |
| Jun 30, 2021 | 61.55% |